Cholestin trademark suit
This article was originally published in The Tan Sheet
Executive Summary
Filed April 14 by Simi Valley, Calif.-based Pharmanex in Salt Lake City, Utah federal court. Lawsuit seeks an injunction against HPF, Inc.' s marketing of Cholestene, a red yeast rice product for healthy cholesterol. Pharmanex argues the product is deceptively similar to Cholestin, which generated sales of more than $3.5 mil. in 1998, according to the firm. Cholestene was launched in health food and mass market stores by Trevose, Penn.-based HPF in January ("The Tan Sheet" April 12, In Brief). Pharmanex also is sending letters to approximately 4,500 independent pharmacists pointing out differences between the two products, including Cholestin's production through a proprietary process using a particular strain of red yeast rice. The firm believes no other red yeast rice product uses the strain found in Cholestin and that HPF's use of clinical studies conducted by Pharmanex is "therefore unwarranted." Cholestin is marketed through direct sales and in some independent pharmacies
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning